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Editorial summary: 
The Archaea metalloproteinase LysargiNase increases proteome coverage, identifies more C-
terminal peptides from proteins and improves methylated peptide identification.  
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To improve proteome coverage and protein C-termini identification we characterized the 
Methanosarcina acetivorans thermophilic proteinase LysargiNase, which cleaves before 
lysine and arginine up to 55°C. Unlike trypsin, LysargiNase-generated peptides have N-
terminal lysine or arginine residues and fragment with b-ion dominated spectra. This 
improves protein C-terminal peptide identification and several arginine-rich phosphosite 
assignments. Uniquely, cleavage also occurs at methylated or dimethylated lysine and 
arginine, facilitating detection of these epigenetic modifications. 
 
Proteomic identification of proteins and posttranslational modifications requires proteolytic 
digestion of proteins into peptides for fragmentation by tandem mass spectrometry and 
identification through spectra-to-sequence matching. The cleavage specificity of the digestion 
enzyme determines peptide length, mass to charge ratio, and sequence and charge position. 
Trypsin is the most commonly used digestion enzyme in proteomics1. Cleaving after arginine 
and lysine, trypsin generates peptides having a C-terminal positively charged residue in addition 
to an N-terminal positive charge from the -amine. This charge distribution results in sequence-
informative collision-induced dissociation (CID) fragmentation spectra dominated by y-type 
ions1,2. However, not all peptides are identified following trypsin digestion: Protein C-terminal 
peptides inherently lack basic residues and are therefore rarely identified without selective 
enrichment3,4 leading to loss of biologically important information on protein structure and 
function5. In addition, cleavage after basic residues in the most common phosphosites, e.g. (R 
or K)n(X)(S or T), can result in ambiguous phosphosite localization. Tryptic cleavage is also 
blocked at modified (e.g. methylated) basic residues and such missed cleavages increase 
peptide length and charge resulting in complex fragmentation spectra that hinders identification 
of the peptide and methylation sites2. Lysine and arginine methylation is an important epigenetic 
and regulatory mechanism for protein-protein interactions and protein function in transcription, 
DNA repair, and signaling6. Hence, new approaches are needed to overcome the problems in 
detecting C-terminal peptides, protein methylation and certain phosphosites. 
 
 New proteases to complement trypsin are much sought after for identification of alternate 
splice forms and the 3,844 “missing” proteins that lack proteomic evidence for their occurrence 
in human tissues7. One such protease is LysN, which selectively hydrolyses peptidyl-lysine 
bonds and so leaves a lysine at the peptide N-terminus. This results in strong b-ion series 
during CID2 and c-ion series during electron transfer dissociation (ETD) fragmentation, enabling 
de novo ladder sequencing of peptides8. LysN also identifies peptides missed in tryptic digests9, 
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allows for enrichment of posttranslational modified peptides based on peptide charge10, and 
cuts before methylated lysines11. However, these benefits are restricted to those LysN-
generated peptides not containing internal arginines or peptides without lysine miscleavage, 
which is reported to be 13% (ref. 12). Moreover, only 71% of all LysN cleavage sites contain an 
N-terminal lysine pointing to poor specificity compared with trypsin12. Thus, we sought a 
protease to address these needs and report the characterization of LysargiNase, a 
metalloproteinase from the Archaea species Methanosarcina acetivorans. We changed the 
original name Ulilysin13 to reflect its exquisite N-terminal selectivity for lysine in addition to its 
previously described peptidyl-arginine specificity13,14. LysargiNase mirrors trypsin specificity and 
overcomes the limitations of LysN in controlled N-terminal placement of basic residues, with the 
added advantage of also cleaving N-terminal to methylated forms of arginine and lysine so 
generating shorter, less complex peptides. 
 
 We compared LysargiNase with trypsin digests of human breast cancer MDA-MB-231 cell 
proteome using high-resolution MS/MS. We identified cleaved peptides in a stringent and 
unbiased manner using non-specific database searches, i.e. spectra-to-sequence matching was 
not restricted by prior information on preferred cleavage sites. 1,096 unique peptides from 
LysargiNase-digests and 1,789 unique tryptic peptides were identified (n=4) (Supplementary 
Tables 1). By extraction of the sequence surrounding the peptide termini we derived 1,917 and 
3,235 unique LysargiNase and trypsin cleavage sites, respectively. LysargiNase showed 
exquisite sequence specificity: 93% of LysargiNase cleavage sites were before arginine (40%), 
as previously reported13,14, but importantly also before lysine (52%) (Fig. 1a). In contrast, 91% 
of tryptic cleavages were after arginine (39%) or lysine (52%). Thus, LysargiNase mirrors trypsin 
cleavage specificity. The number of peptide identifications was improved when we applied the 
new specificity information to restrict the search space during spectrum-to-sequence 
assignment with 2,956 LysargiNase peptides (Supplementary Table 2) and 4,203 tryptic 
peptides identified (Supplementary Table 3). Similar to trypsin15, basic residues in missed 
LysargiNase cleavage sites were frequently preceded or followed by proline (Supplementary 
Fig. 1). LysargiNase fidelity also compared favorably to the lysine content (71%) at cleavage 
sites reported for LysN12. However, as LysN peptides frequently contain internal arginine or 
miscleaved lysines experimentally observed LysN peptides are longer on average, 18.0 
residues in length12, versus 14.2 residues for LysargiNase. 
 
 Confirming the applicability of LysargiNase for proteomics we found that LysargiNase was 
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active in a variety of conditions and solvents commonly used in sample preparation and at 
dilutions down to 1:100 enzyme:proteome ratios (Supplementary Fig. 2). We used 1:50 since it 
represents a similar molar ratio as 1:100 trypsin, enabling a fair comparison. LysargiNase 
showed notable thermophilicity at 55°C retaining 100% activity compared to 25°C, which aids 
digestion by maintaining denaturation (Supplementary Fig. 2f). LysargiNase exhibited tri-, di- 
and moderate carboxypeptidase activity at lysine or arginine residues using synthetic peptides 
(Supplementary Fig. 3). Yet, when trypsin-digested BSA was used as substrate only 2 of 10 
peptides were processed at their carboxy terminus and no amino- or diaminopeptidase activity 
was observed (Supplementary Fig. 4). LysargiNase proved suitable for in gel digestion of β-
casein and bovine serum albumin (Supplementary Fig. 5). 
 
 LysargiNase aided peptide identification and hence proteome coverage by several means. 
Compared with trypsin, very different LysargiNase-fragment ion sequences retain the basic 
residue after CID ion trap fragmentation and so exhibited strong b-ion series (Fig. 1b, 
Supplementary Fig.6a). Corresponding spectra of tryptic peptides identified with identical 
cleavage site basic residues were dominated by y-type fragment ions (Fig. 1b, Supplementary 
Fig. 7). This led to different coverage of the precursor peptide sequence and resulted in 
different search engine scores. Secondly, corresponding peptides can differ where the cleavage 
site basic residue is different (Supplementary Fig. 8), which can also alter peptide ionization 
and fragmentation1. However, fragment ions of the y-series are more stable than b-ions16, 
resulting in more tryptic peptide identifications than from LysargiNase (Supplementary Fig. 6b). 
Indeed, we observed extensive a-ion fragments in a LysargiNase proteome digest analyzed by 
beam-type CID fragmentation (Supplementary Fig. 9a). Including these a-ions in Comet 
XCORR scoring significantly increased quality (P<0.0001), but not the number of LysargiNase 
peptide identifications (Supplementary Fig. 9b). Hence, complementary use of both proteases 
increased proteome coverage—1,347 unique peptide sequences were identified in LysargiNase 
digests that were not identified following trypsin cleavage (Supplementary Fig. 6b). A 
considerable overlap in peptide identifications resulted from the complementary fragmentation 
spectra (n=1,558), increasing confidence in identification of these sequences. Finally, 
LysargiNase peptides included significantly more protein C-terminal peptides in four 
independent experiments by now having a lysine or arginine at their N-terminus compared with 
those generated by trypsin, where all basic residues are lost (P<0.001, Fig. 1d, Supplementary 
Fig. 10, Supplementary Tables 4 and 5). 
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 We TiO2-enriched SILAC-labeled phosphopeptides from MDA-MB-231 cells. The identified 
phosphosites were stringently filtered for those with a MaxQuant localization site probability 
>0.75 (ref. 17) and phosphorylation motifs were determined using MotifX18. Compared with 
trypsin, LysargiNase phosphopeptides showed a higher representation of RxS and RxxSP sites 
and phosphorylation motifs containing proline (Fig. 1e and Supplementary Figures 11 and 12). 
Thus, LysargiNase benefits detection of sites phosphorylated by certain kinases e.g. protein 
kinase C, ERK and CDK5, which prefer RxS and RxxSP motifs17. After 5 and 20 min stimulation 
with 12-O-tetradecanoylphorbol-13-acetate, phosphopeptides with these sites accumulated 
(Supplementary Fig. 11) in agreement with stimulation of the protein kinase C family19. 
 
 We verified the LysargiNase cleavage specificity by PICS (proteomic identification of 
protease cleavage sites), which determines cleavage sites after incubation with database-
searchable proteome-derived peptide libraries generated by chymotrypsin (Fig. 2a) and GluC- 
(Fig. 2b) digestion and subsequent dimethylation of lysine -amines20. The dimethyl-lysine 
modification restricted trypsin cleavage to arginine residues as reported20, whereas LysargiNase 
also cleaved before the dimethylated lysines. Using MALDI-TOF-MS we verified this flexible 
specificity by demonstrating cleavage of synthetic peptide substrates containing dimethylated 
lysine, but not acetylated lysine (Fig. 2c). Further confirmation came from LysargiNase 
digestion of dimethylated E. coli proteome (n=2) in which 49% and 43%, respectively, of the 
beam type CID-identified peptides were cleaved before dimethylated lysine. In comparison, only 
5% and 6% of tryptic peptides had a C-terminal dimethylated lysine (Supplementary Table 6). 
In MDA-MD-231 cell proteomes we also identified natural mono-methylated (Supplementary 
Fig. 13) and dimethylated (Supplementary Fig. 14) N-terminal lysines following LysargiNase 
digestion. Thus, LysargiNase accepts unmodified, mono-methylated and dimethylated lysine at 
P1’ as shown in the structural model (Supplementary Fig. 15), but kinetically prefers 
unmodified lysine. 
 
 This unusual tolerance of methylated lysines is noteworthy as it is challenging to identify such 
peptides due to the presence of highly charged and often long tryptic peptides arising from 
missed cleavages6. Therefore, we posited that LysargiNase would also cut at methylated 
arginine. We found that LysargiNase cleaved mono-methylated and dimethylated arginines in 
MDA-MD-231 proteomes (Supplementary Figures 13 and 14). This was further characterized 
using synthetic peptides containing mono-methylated and asymmetric or symmetric 
dimethylated arginine (Fig. 2d), whereas trypsin cut essentially only after unmodified arginine. 
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Moreover, we observed a significantly higher number of peptides containing a methylated 
(P<0.05) or dimethylated (P<0.001) arginine or lysine in the LysargiNase-digested MDA-MD-
231 proteome as compared to trypsin (Supplementary Fig. 15b). Overall, the thermophilic 
LysargiNase is a powerful complement to trypsin in proteomics. 
 
 
METHODS 
Methods and any associated references are available in the online version of the paper at 
http://www.nature.com/naturemethods/. 
Note: Supplementary information is available on the Nature Methods website. 
Accession codes. The mass spectrometry raw data and associated peptide identification 
details are deposited in ProteomeXchange with the dataset identifiers <PXD001113, 
PXD001114, PXD001121, PXD001122, PXD001378, and PXD001379>. 
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Figure 1 |LysargiNase cleavage specificity and application in shotgun and phosphoproteomics. 
(a) Frequency distribution plots of cleavage sites identified by ion trap CID from human 
proteomes (n = 4) digested with LysargiNase (n = 1,917) and trypsin (n = 3,235). .Sequences 
were aligned at cleavage sites between P1 and P1’ and normalized to the natural human amino 
acid abundances. (b) Exemplary spectra of the peptide KAAIDWFDG (precursor [M+2H]2+ 
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511.7507 m/z) identified in a LysargiNase digested proteome and the corresponding peptide 
AAIDWFDGK (precursor [M+2H]2+ 511.7507 m/z) from a tryptic digest. (c) Sequence coverage 
by b-type and y-type fragment ions observed in 8,463 ion trap CID peptide spectra matches for 
trypsin and 5,474 for LysargiNase (FDR < 0.01). The centerlines show the medians, box limits 
indicate the 25th and 75th percentiles, whiskers extend to the 5th and 95th percentiles, and 
outliers are represented by dots. (d) Protein C- and N-terminal as a proportion of all peptides 
identified by shotgun proteomics after trypsin (white) or LysargiNase (grey) cleavage of 
proteomes (n = 4). (e) Phosphorylation motifs in trypsin and LysargiNase-digested proteomes 
identified by motif-x, number and proportion of matching high confidence phosphopeptides. 
having a localization probability > 0.75 identified by MaxQuant at an FDR < 0.01.. Phosphosites 
matching selected kinase specificity as extracted from the human protein reference database 
a43 shown as heatmaps. Significance of differences was tested using the two-tailed Student’s t-
test (*P < 0.05, **P < 0.01, ***P < 0.001). 
  
Figure 2 |LysargiNase cleavage at methylated and dimethylated Arginine and Lysine. (a) 
Frequency distribution plots of LysargiNase (n = 126) and trypsin (n = 54) cleavage sites 
identified in chymotrypsin-generated E. coli proteome peptide libraries by PICS. K* designates 
dimethylated lysine. (b) LysargiNase sites (n = 316) and trypsin cleavage sites (n = 190) 
identified from E. coli GluC libraries by PICS. Sequences were aligned at cleavage sites 
between P1 and P1’ and normalized to the natural E. coli amino acid abundances. (c) MALDI-
TOF MS LysargiNase cleavage assays of RSGTLTYEAV↓KQTTD: peptide K1 (unmodified 
lysine and N-terminus, theoretical [M+H]+ 1,669.83 m/z), peptide K1 with dimethylated lysine 
and N-terminus (K1-dm, [M+H]+ 1,725.89 m/z), and peptide K1 with acetylated lysine and N-
terminus (K1-ac, [M+H]+ 1,753.85 m/z). The N-terminal LysargiNase cleavage products are 
RSGTLTYEAV (unmodified K1, [M+H]+ 1,096.56 m/z; K1-dm, [M+H]+ 1,124.59 m/z; and K1-ac, 
[M+H]+ 1,138.59 m/z). The C-terminal cleavage product KQTTD is not observed. (d) MALDI-
TOF MS cleavage assays of WGGYS↓RGGYGGW by LysargiNase and WGGYSR↓GGYGGW 
by trypsin: peptide R1 ([M+H]+ 1,302.53 m/z), peptide R1 with mono-methylated arginine (R1-
MMA, [M+H]+ 1,316.53), peptide R1 with asymmetric arginine dimethylation (R1-aDMA, [M+H]+ 
1,330.56), and peptide R1 with symmetric arginine dimethylation (R1-sDMA, [M+H]+ 1,330.56). 
C-terminal LysargiNase cleavage products are RGGYGGW (R1, [M+H]+ 752.34; R1-MMA, 
[M+H]+ 766.36 m/z; R1-aDMA and R1-sDMA, [M+H]+ 780.37) and N-terminal tryptic cleavage 
products are WGGYSR (R1, [M+H]+ 725.33; R1-MMA, [M+H]+ 739.35 m/z; R1-aDMA and R1-
sDMA, [M+H]+ 753.36). The corresponding N-terminal LysargiNase cleavage product WGGYS 
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and the C-terminal tryptic fragment GGYGGW were not detected. For each peptide, overlaid 
MALDI-TOF MS spectra show control reactions (grey curve; bottom layer), LysargiNase digest 
(orange; top layer) and tryptic digest (light blue; middle layer). Substrate ion peak m/z is 
indicated in grey, product ion peaks in orange and light blue for cleavage by LysargiNase and 
trypsin, respectively. Spectra are normalized to the peak intensity of the most intense ion peak. 
 
ONLINE METHODS 
LysargiNase purification and activation. Wild-type LysargiNase (alias ulilysin) from 
Methanosarcina acetivorans was expressed and purified as the zymogen proform as described 
for the C269A mutant13. Aliquots of proLysargiNase were activated by stepwise addition 10 mM 
CaCl2 buffered in 50 mM HEPES, pH 7.5 and incubated for 12 to 16 h at 20 °C. 
 
Characterization of LysargiNase activity. LysargiNase activity was assayed with resorufin-
labeled casein (Universal Protease Substrate, UPS) at an enzyme: substrate ratio of 1:400 in 50 
mM HEPES, 10 mM CaCl2, pH 7.5, with varying concentrations of chemicals and solvents 
commonly used in proteomics added as indicated (Figures 1 and 2). Assays were performed 
for 30 min at 37 °C or at the temperatures shown in the figure and stopped by addition of 5% 
TCA, followed by neutralization with 1.5 M Tris-HCl, pH 9.0. Fluorescence was measured using 
an excitation wavelength 544 nm and emission wavelength 590 nm on a fluorescence 
microplate reader (Molecular Devices fmax). These assay conditions were designed to generate 
less than 50% of the maximal fluorescence in the control reactions without added chemicals 
(data not shown) so as to quantify the effect of the different conditions. For proteome digestion 
efficiency assays, human MDA-MB-231 cell proteome was digested with LysargiNase 
(enzyme:substrate ratio 1:100) at 37 °C, 18 h in 50 mM HEPES,10 mM CaCl2, pH 7.5, and the 
chemicals as indicated in the figure. Digestion efficiency was visualized by 12% SDS-PAGE and 
Coomassie brilliant blue R250 staining. 
 
MALDI-TOF based exopeptidase activity assay. Synthetic peptides were dissolved and 
diluted 1:100 in HPLC grade water to a final concentration of 10 ng/μl. A tryptic BSA library was 
prepared by incubating 100 μg of BSA (Sigma) with 1.0 μg of Trypsin Gold (Promega) in 50 μl of 
10 mM HEPES, 10 mM CaCl2, pH 7.5, 37 °C. The digestion was stopped before completion 
after 2 h by adding the serine protease inhibitor AEBSF (Sigma) to a final concentration of 1.0 
mM. LysargiNase was incubated with synthetic peptides (10 ng) or 1 μg of the tryptic BSA 
mixture in 10 mM HEPES, 10 mM CaCl2, pH 7.5 for 18 h at 37 °C. Reactions were stopped by 
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adding trifluoroacetic acid (TFA) to a final concentration of 0.1%. One microliter of sample was 
spotted in duplicate on a MALDI target plate and mixed with the equal volume of alpha-cyano-4-
hydroxycinnamic acid  (CHCA) (5 mg/ml in 70% acetonitrile and 0.1% TFA). Samples were 
desalted on-plate by two washes with 1.0 μl of ice cold 0.1% TFA. Samples were analyzed 
using a Voyager-DE STR MALDI-TOF mass spectrometer (Applied Biosystems). Baseline 
reduction and noise removal were performed using Data Explorer™ version 4.5. 
 
In vitro assays with synthetic peptide substrates. To test cleavage at modified lysine 
residues, synthetic peptide K1 (sequence RSGTLTYEAVKQTTD, obtained from Genescript) 
was modified by reductive dimethylation using isotopically light formaldehyde and sodium 
cyanoborohydride21 or acetylated using NHS-activated acetate (Pierce). Unmodified or modified 
K1 peptides were incubated with LysargiNase or trypsin at a molar ratio of 1:100 in 50 mM 
HEPES, 5 mM CaCl2 for 3h at 37°C. Cleavage at modified arginine residues was tested with 
peptide R1 (sequence WGGYSRGGYGGW), obtained with unmodified, monomethylated, 
asymmetric dimethylated or symmetric dimethylated arginine, was incubated with LysargiNase 
or trypsin at a molar ratio of 1:50 in 50 mM HEPES, 5 mM CaCl2, pH 7.5 for 16 h at 37 °C. All 
peptide cleavage reactions were terminated dilution with 25 x excess of 5 mg/ml CHCA 
dissolved in 80% ACN, 0.1% TFA. Cleavage assays with synthetic peptide substrates were 
spotted on a MALDI target (1 μl of reaction mixture in 5 mg/ml CHCA in 80% ACN, 0.1% TFA), 
air-dried and analyzed using a 4700 series MALDI-TOF/TOF mass spectrometer (Applied 
Biosystems) in positive ion reflector mode. 
 
Modeling of protein structure. Structural models of the LysargiNase are based on the 
experimental crystal structure of the enzyme with an arginine-valine dipeptide occupying the S1’ 
and S1’ pockets (Protein Data Bank access code 2CKI)13. Models were generated using the 
UCSF Chimera software suite22 with LysargiNase displayed in standard orientation23. 
 
Cell culture and proteome preparation. For shotgun experiments, MDA-MB-231 cells (ATCC), 
previously tested for mycoplasma contaminations, were cultured in DMEM (Gibco) 
supplemented with 10% Cosmic Calf Serum, 10,000 U/ml penicillin G and 100 µg/ml 
streptomycin and non-essential amino acids (Gibco). Cells were detached using Versene and 
gentle scraping, collected by centrifugation and lysed in 100 mM HEPES, 150 mM NaCl, 5 mM 
EDTA, 5 mM EDTA, pH 7.5 supplemented with protease inhibitors (Complete Protease 
Inhibitors, Roche) and phosphatase inhibitors (PhosStop, Roche). Protein concentrations were 
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determined using the BioRad protein assay (BioRad). For the 12-O-tetradecanoylphorbol-13-
acetate stimulation experiments, MDA-MB-231 cells were SILAC labeled with L-arginine (21 
mg/liter) and L-lysine (36.5 mg/liter) for light-labeled (Arg0, Lys0) cells (Sigma-Aldrich), L-
arginine-13C6 (21.75 mg/liter) and L-lysine-D4 (37.5 mg/liter) for medium-labeled (Arg6, Lys4) 
cells, L-arginine-13C615N4  (22.25 mg/liter) and L-lysine-13C615N2 (38.5 mg/liter) or heavy-labeled 
(Arg10, Lys8) cells (Cambridge Isotope Laboratories) as previously described for HeLa cells17. 
Labeled cells were serum starved for 16 h (six 15 cm dishes per condition; 95% confluent cells) 
before stimulation. Light-labeled cells were treated with 0.1% DMSO in serum-free medium for 0 
min (replicates 1 and 2) or 5 min (replicates 3 and 4) and medium- and heavy- labeled 
stimulated with 200 ng/ml 12-O-tetradecanoylphorbol-13-acetate, 0.1% DMSO in serum-free 
medium for 5 min and 20 min, respectively. 
 
E. coli proteome preparation and digestion. E. coli strain K12 was grown in LB broth before 
harvesting by centrifugation. Cells were washed with twice with 50 mM HEPES, pH 7.5 before 
snap freezing in liquid nitrogen. Cells were lysed by thawing in 50 mM HEPES with added 
protease inhibitor cocktail (100 μM PMSF, 1 μM 1,10-Phenantroline, 1 μM E-64, 1 μM pepstatin), 
pH 7.5, followed by sonication and centrifugation to remove cell debris. The soluble E. coli 
proteome was reduced and denatured in 2 M Guanidine hydrochloride and 1 mM TCEP (60 min, 
60 °C), followed by alkylation with 5 mM iodoacetamide (45 min, 60 °C, dark). Two aliquots of 
the E. coli proteome were further modified by reductive dimethylation with 25 mM sodium 
cyanoborohydride and 25 mM light formaldehyde24. Both modified and unmodified E. coli 
proteomes were digested with LysargiNase and trypsin in 50 mM HEPES, 10 mM CaCl2, pH 7.5 
at an enzyme:proteome ratio of 1:100 (w/w), 37 °C, 18 h. 
 
Shotgun proteome preparation. Generally, proteome aliquots of approximately 1 mg were 
denatured by addition of 3.5 M guanidinium-HCl, 10 mM DTT (30 min, 65 °C) and alkylated 
using 50 mM iodoacetamide (30 min, 20 °C, in the dark) and purified by chloroform/methanol 
precipitation25. For shotgun proteomics experiments, precipitated proteins were dissolved in 50 
mM NaOH, immediately diluted 10-fold and neutralized by addition of water and buffer to a final 
concentration of 50 mM HEPES, 10 mM CaCl2, pH 7.5. Proteins were digested with 
LysargiNase (proteome:enzyme ratio 50:1 w/w) or trypsin gold (Promega, 100:1 w/w) at 37 °C 
for 16 h. Note that this corresponds to an approximately equal mole enzyme/substrate ratio 
since the molecular mass of pro-LysargiNase (39 kDa) is almost twice that of trypsin (23.4 kDa). 
Digests were clarified by centrifugation, and an aliquot of 20 μg digested protein desalted using 
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C18 STAGE tips26. 
 
Phosphopeptide enrichment. For phosphopeptide analysis, protein pellets were dissolved in 8 
M urea, 2 M thioruea to avoid loss of phosphorylation at high pH, diluted 5-fold with 50 mM 
HEPES, 10 mM CaCl2, pH 7.5 and digested with LysargiNase (50:1 w/w) or trypsin gold 
(Promega, 100:1 w/w) for 16 h at 30 °C. Digests were clarified by centrifugation, peptides 
acidified and desalted with a C18 cartridge (SepPak, Waters). Phosphopeptides were enriched 
from four independent unstimulated MDA-MB-231 cell proteomes and from cell proteomes of 
four independent 12-O-tetradecanoylphorbol-13-acetate stimulation experiments at 5 min and 
20 min. At each point, two replicates were enriched from two independent MDA-MB-231 cell 
proteomes using custom made TiO2 tips as described17 and two replicates were enriched using 
commercial TiO2 phosphopeptide enrichment kit (Sigma). All peptide samples were desalted 
using C18 STAGE-tips26 and stored on-tip until mass spectroscopy analysis. 
 
Proteomic Identification of protease cleavage site specificity (PICS). PICS was performed 
as described27. In brief, E. coli-derived proteome peptide libraries were generated by digestion 
with GluC or chymotrypsin followed by amine-modification by reductive dimethylation. Libraries 
(200 μg) were incubated with trypsin or LysargiNase at an enzyme:peptide library ratio of 1:100 
(w/w). Free N-terminal amine groups of fragment peptides, generated by substrate peptide 
cleavage, were tagged with an N-terminal modification with a redox-cleavable biotin moiety and 
enriched by streptavidin capture, eluted and desalted with C18 OMIX tips (Varian). 
 
Mass spectrometry. For shotgun and phosphoproteomics experiments, peptides were eluted 
from STAGE tips in mobile phase 80% acetonitrile (ACN), 0.1 % formic acid, SpeedVac 
concentrated to near-dryness and dissolved in approximately 20 μl mobile phase 2% ACN, 
0.1% formic acid. Ten microliters were loaded on the column. Shotgun experiments were 
analyzed on a nanoHPLC systems (Thermo Scientific) coupled to an LTQ-Orbitrap hybrid mass 
spectrometer (LTQ-Orbitrap XL, Thermo Scientific, operated by the UBC Centre for High 
Throughput Biology) using a nanospray ionization source consisting of a fused silica trap 
column (length 2 cm, inner diameter 100 μm, packed with 5- μm diameter Aqua C-18 beads; 
Phenomenex), fused silica fritted analytical column (length 20 cm, inner diameter 50 μm, 
packed with 3 μm diameter Reprosil-Pur C-18-AQ beads; Dr. Maisch GmbH) and a silica gold 
coated spray tip (20 μm inner diameter, 6 μm diameter opening, pulled on a P-2000 laser puller; 
Sutter Instruments; coated on EM SCD005 Super Cool Sputtering Device; Leica Microsystems). 
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Buffer A consisted of 0.5% acetic acid, and buffer B consisted of 0.5% acetic acid and 80% 
acetonitrile. Gradients were run from 0% B to 15% B over 15 min, then from 15% B to 40% B in 
the next 65 min, then increased to 100% B over 10 min period, held at 100% B for 30 min. The 
LTQ-Orbitrap was set to acquire a full-range scan at 60,000 resolution from (m/z 350–1800) in 
the Orbitrap and to simultaneously fragment the top five peptide ions in each cycle in the LTQ 
(minimum intensity 200 counts). Parent ions were then excluded from MS/MS for the next 180 
sec. The Orbitrap was continuously recalibrated against protonated (Si(CH3)2O)6; at m/z = 
445.120025 using the lock-mass function28. 
 
Enriched phosphopeptides were analyzed by nanoHPLC-MS/MS using the LTQ-Orbitrap XL 
setup as above or with a hybrid quadrupole-Orbitrap mass spectrometer (QExactive, Thermo 
Scientific) coupled online with a RSLC nanoHPLC (Ultimate 3000, Thermo Scientific). Samples 
were loaded on a 100 μm, 2 cm nanoviper pepmap100 trap column (Thermo Scientific) in 2% 
ACN, 0.1% formic acid at a flow rate of 15 μl/minute. Peptides were eluted and separated at a 
flow rate of 300 μl/minute onto a RSLC nanocolumn 75 μm x 15 cm, pepmap100 C18, 3 µm 100 
Å pore size (Thermo Scientific), with a linear ACN gradient from 2% to 24% in 0.1% formic for 
25 minutes acid followed by a linear increase to 30% ACN in 0.1% formic acid over 5 minutes 
and additional increase up to 80% ACN in 0.1% formic acid over 5 minutes, followed re-
equilibration at 2% ACN. The eluent was nebulized and ionized using a nanoelectrospray 
source (Thermo Scientific) with a distal coated fused silica emitter (New Objective) with a 
capillary voltage of 1.8-2.2 kV. The QExactive instrument was operated in the data dependent 
mode to automatically switch between full scan MS and MS/MS acquisition. Survey full scan MS 
spectra (m/z 350–1850) were acquired in the Orbitrap with 70,000 resolution (m/z 200) after 
accumulation of ions to a 3 × 106 target value with maximum injection time of 120 ms. Dynamic 
exclusion was set to 30 sec. The 10 most intense multiply charged ions (z ≥ 2) were 
sequentially isolated and fragmented in the octopole collision cell by HCD with a fixed injection 
time of 60 ms 17,500 resolution and AGC target of 1 × 105 counts. A 2.7 Da isolation width was 
chosen. Underfill ratio was at 10% and dynamic exclusion was set to 30 sec. Typical mass 
spectrometric conditions were as follows: spray voltage, 2 kV; no sheath and auxiliary gas flow; 
heated capillary temperature, 275 °C; normalized HCD collision energy 27%. 
 
E. coli proteome digests and PICS assays were analyzed using a quadrupole time-of-flight 
mass spectrometer (QStar XL, Applied Biosystems, operated by the UBC Centre for Blood 
Research Mass Spectrometry Suite) coupled on-line to an LC Packings capillary LC system 
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(Dionex). Peptide samples were diluted in 0.3% formic acid, loaded onto a column packed with 
Magic C18 resin (Michrom Bioresources) and eluted using a 0–80% gradient of organic phase 
over 95 min. Buffer A was 2% ACN with 0.1% formic acid and buffer B was 80% ACN, 0.1% 
formic acid. ESI ionization tip ionization voltage was 25,000 V. MS data were acquired 
automatically using the Analyst QS software, v1.1 (Applied Biosystems) with information-
dependent acquisition based on a 1s MS survey scan from 350 m/z to 1500 m/z, followed by up 
to 3 MS/MS scans of 2 s each. Nitrogen was used as the collision gas.  
 
In gel digestion. The standard proteins BSA and β-casein were resolved by 12% SDS-PAGE. 
Bands were stained with Coomassie G-250 and then excised, destained thrice with 60% 
acetonitrile, 20 mM ammonium bicarbonate, washed in 100% acetonitrile and lyophilized. Gel 
bands were rehydrated with either 10 μL trypsin in 20 mM ammonium bicarbonate (12 ng/μL) or 
10 μL LysargiNase (40 ng/μL) by passive diffusion for 1 h, 4 °C. Excess solution was removed, 
and 10 μL 20 mM ammonium bicarbonate 10 mM CaCl2 was added to the gel plugs and 
digested overnight at 37 °C. Digests (1 μL on column) were analyzed by LC-MS/MS using an 
Agilent G4240A ChipCube interfaced directly to an Agilent G6550A Q-TOF mass spectrometer 
(Agilent Technologies). Peptides were diluted with buffer A (0.1% formic acid) and resolved by a 
35 min linear gradient on a reversed-phase chip (75 μm x 150 mm, Zorbax 300SB-C18) from 
3% buffer B (99.9% acetonitrile, 0.1% formic acid) to 60% buffer B at 300 nL/min. Peptides were 
ionized by ESI (1.8 kV) and mass spectrometry analysis was performed in positive polarity, with 
precursor ions detected from 350-1500 m/z. The top three ions per scan were selected for CID 
using a narrow (1.3 amu) exclusion window and an MS/MS scan rate of 2 spectra/second. 
Precursor ions were then excluded from further CID for 30 s. Data files were converted into .mgf 
files using Agilent MassHunter Qualitative Analysis B.06.00 and the files searched using Mascot 
v2.4 (Matrix Science). Search parameters included 0.3 Da tolerance for MS and MS/MS, 
UniProt-SwissProt database with 'all entries' enabled, variable oxidation of methionine, variable 
propionamide of cysteine, and a maximum of 2 missed cleavages. 
 
Spectrum-to-sequence matching. Shotgun and phosphoproteomics data acquired with the 
Orbitrap XL and QExactive spectra where matched to peptide sequences in the human UniProt 
protein database (October 2013) with appended standard laboratory and common 
contamination protein entries and reverse decoy sequences (in total 177,324 entries) using the 
Andromeda algorithm29 as implemented in the MaxQuant software package v1.4.12 (ref. 30), 
using an peptide FDR of 0.01. Search parameters included a mass tolerance of 5 ppm for the 
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parent ion, 0.5 Da for the fragment ions in LTQ-Orbitrap XL data and 20 ppm for fragment ions 
in QExactive data, carbamidomethylation of cysteine residues (+57.021464 Da), variable N-
terminal modification by acetylation (+42.010565 Da), and variable methionine oxidation 
(+15.994915 Da). Non-specific searches of proteome digest were performed to probe the 
cleavage site specificity of LysargiNase. Specific searches of the same datasets used {X|KR} 
and {KR|X} as simple cleavage site rules for LysargiNase and trypsin, respectively, additionally 
considered Arg and Lys methylation (+14.01565 Da) and dimethylation (+28.031300 Da) as 
variable modifications and allowed up to three missed cleavages. Phosphoproteome data 
analysis additionally considered variable phosphorylation (+79.966331 Da) at Ser, Thr and Tyr, 
and in the case of 12-O-tetradecanoylphorbol-13-acetate stimulation experiments triple SILAC 
labeling (Arg +6.020129, Lys +4.025107 and Arg+10.008269, Lys +8.014199 for medium and 
heavy labels, respectively). 
 
Peak lists of QSTAR XL data were created using the Analyst QS software v1.1 (Applied 
Biosystems) and converted to the mzXML format using msConvert. Spectra were matched to 
peptides sequences in the UniProt E. coli K12 proteome database (downloaded Nov 22, 2013) 
with appended standard laboratory and common contamination protein entries and reverse 
decoy sequences (9,134 entries total) using X!Tandem31 (E. coli proteome data) or Mascot v2.3 
and X!Tandem31 (for PICS data) in conjunction with PeptideProphet32 and iProphet33 as 
implemented in the Trans Proteomic Pipeline v4.6(ref. 34) at an estimated FDR of 0.05. Search 
parameters included a mass tolerance of 200 ppm for the parent ion and 0.2 Da for the 
fragment ions, semi-specific restriction enzyme cleavages for chymotrypsin or GluC (PICS) or 
specific enzyme cleavage with LysargiNase or trypsin (E. coli proteome) with up to two missed 
cleavages. E. coli proteome data searches considered the following peptide modifications: 
Carbamidomethylation of cysteine residues (+57.021464 Da), dimethylation of lysine ε-amines 
(+28.031300 Da) and variable methionine oxidation (+15.994915 Da). PICS data searches also 
considered thioacylation of peptide N-termini (+87.998285 Da). 
 
For analysis of a-ions in beam-type fragmentation data, QStar .wiff files were converted to 
.mzXML using msConvert and used as input for the TransProteomic Pipeline v4.7 rev1. Data 
was searched with Comet35 as part of TPP using 0.2 Da tolerance for MS and MS/MS, 
LysargiNase specificity {X|KR}, variable oxidation of methionine (+15.994915 Da), 2 missed 
cleavages and scoring for y-ions and b-ions. Additionally, an independent search was used with 
a-ions also included as part of the scoring. XCORR scores for peptide spectrum matches were 
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extracted from pepXML files and compared to determine the a-ion scoring effect. 
 
Data analysis. For shotgun proteomics peptide identifications the sequence context 
surrounding the N- and C-termini of the identified peptides was extracted from the database. For 
determination of the cleavage site specificity, all peptide termini identified by database searches 
without enzyme constraints were considered as LysargiNase or trypsin cleavage sites unless 
they mapped to protein termini. This resulted in the definition of {X|KR} as cleavage specificity of 
LysargiNase that was used in all subsequent searches. b-ion and y-ion counts were extracted 
from the MaxQuant result files, and fragment coverage calculated by dividing the number of 
matched ions by the sequence length. 
 
Phosphorylation motives were extracted using the motif-x webservice18,36. Phosphorylated 
peptide identifications obtained in all experiments after digestion with trypsin or LysargiNase 
were searched separately using the following settings: foreground format: pre-aligned; central 
character: S; width: 15; occurrences: 20; significance: 0.000001; background: IPI human 
proteome. The motifs identified by were merged and for each motif the number of occurrences 
within the pool of phosphorylated peptides identified in the LysargiNase and trypsin datasets 
counted by regular expression matching. For comparison of the proportion of each motif in the 
LysargiNase and trypsin datasets, the occurrence was calculated as percent difference and 
significance tested using Pearson’s chi-squared p-value. Only motifs describing at least 5% of 
the phosphorylated peptides identified by trypsin or LysargiNase digestion are reported.  
 
To link observed phosphorylation motifs to kinase activity we retrieved known kinase sequence 
specificities from HRPD v9(ref. 37). For each identified phosphorylation motif all corresponding 
phosphorylation sites in our joint trypsin and LysargiNase datasets were counted, matched to 
kinase specificity by regular expression search and the percentage of sites potentially targeted 
by a specific kinase calculated. Only kinases matching at least one of the phosphorylation site 
motifs identified in the dataset are reported. 
 
Protease cleavage sites were inferred by database searches from the peptides identified by 
mass spectrometry, which represent the prime side cleavage products of substrate cleavages, 
using a web-based tool (available at http://clipserve.clip.ubc.ca/pics) as described27. Cleavage 
site specificity logos were generated with the iceLogo web tool38 using standard settings. 
Boxplots were generated using the BoxPlotR web server39. 
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